Introduction
The (9;22) Philadelphia translocation of chronic myelogenous leukemia (CML)' was the first described nonrandom translocation in malignancy, and has now been molecularly identified with the structurally and functionally abnormal chimeric protooncogene bcr-abl (1) (2) (3) (4) (5) . CML evolves clinically to more advanced stages through the sequential acquisition of additional cytogenetic abnormalities, a pattern which has recently been demonstrated in common solid tumors as well (6) (7) (8) .
Despite these important advances in our understanding of CML, the process by which the affected malignant clone maintains its proliferative advantage in vivo remains unknown, de-enous leukemia; IMDM, Iscove's modified Dulbecco's medium; LFA-3, lymphocyte function antigen-3; PI, phosphatidyl-inositol; PNH, paroxysmal nocturnal hemoglobinuria. spite extensive in vitro investigation. When grown in shortterm colony forming assays, CML progenitor cells appear to display the same dependence on hematopoietic growth factors as do normal progenitors. In long-term liquid cultures, progenitors arising from the CML clone survive less well than do normal progenitors, and actually disappear over time leaving behind only normal cells (9) . Finally, while in vivo IFN,, treatment ameliorates or totally reverses the proliferative advantage ofthe CML clone, with 15-25% ofcases experiencing complete cytogenetic remission (10) , no in vitro assay to date has identified a selective effect of IFNa on CML versus normal hematopoietic cells.
Several lines of circumstantial evidence suggests that CML progenitor cells are deficient in their expression of cell surface cytoadhesion molecules. First, Gordon et al. found that CML progenitor cells adhered poorly to bone marrow stromal monolayers in vitro, and more recently have suggested that normal progenitor cell stromal adhesion is mediated through a phosphatidyl-inositol(PI)-linked surface receptor (1 1, 12). Next, the cytochemical hallmark of CML is decreased expression of the PI-linked ectoenzyme leukocyte alkaline phosphatase (13). Finally, lymphocyte function associated antigen three (LFA-3, CD58) whose cell surface expression can be linked through PI, has been found to be underexpressed in EBV-transformed cell lines, leading to their escape from immune surveillance and suppression by autoreactive T lymphocytes (14) . Taken together, these observations suggest that deficient expression of critical progenitor cell cytoadhesion molecules, including those which include PI-linked isoforms such as LFA-3, might contribute to the pathophysiologic clonal expansion ofthe CML clone in vivo.
We (17) . Methylcellulose from adjacent portions of the culture plates was plucked and processed in parallel, and RNA from the K562 cell line and normal human bone marrow were processed as positive controls as well. cDNA was synthesized with reverse transcriptase using a specific primer present in both normal and rearranged bcr messages.
The cDNA was divided in halffor assay ofboth normal abland bcr abl.
First round PCR primers and nested primers for bcr-abl were as described (I17), and nested primers for second round normal abl amplification were GCTCCGGCCCGATCGTTCGCTTGGCGCAAA for exon la, GACCAAAGAAGGCCAAGCTTGCCTGCCCTG for exon lb, and CTCAGACCCTGAGGCTCAAAGTCAGATGCT for 3' abl sequence. The polymerase chain reaction (I18, 19) was performed with Taq polymerase by denaturation at 94°C for 1 min and primer extension at 720C for 2 min, for 35 rounds with no annealing step. In 11/12 samples normal abl as well as bcr-abl could be detected on an ethidium bromide-stained gel. DNA from all 12 colonies was transferred after electrophoresis to Genescreen and hybridized with end-labelled internal 3' abl oligonucleotide, at 50'C by the method of Church and Gilbert (20), to confirm the identity ofthe visualized PCR products and to score samples in which the PCR product could not be visualized directly on a gel.
Stimulation of autologous proliferating T cells in response to progenitors (APLR). Highly enriched CML or normal bone marrow progenitor cells were prepared by removing contaminating nonprogenitor cells (T cells, B cells, NK cells, myeloid and erythroid precursors) by negative immunoselection on plastic dishes (15, 16) , and irradiated with 20 Gy. I05 autologous CD5' T cells were incubated with I05 irradiated progenitor cells for 8 d, the cultures pulsed with 3HTdR for 16 h, and the cells were harvested. T cell proliferation was measured by the stimulation index, i.e., the ratio of 3H incorporation into T cells stimulated with progenitor cells, versus 3H incorporation into unstimulated T cells (21) .
Results
CML progenitor cells are deficient in the expression ofcell surface LFA-3 (CD58). Bone marrow mononuclear cells from a normal donor, and from a patient with newly diagnosed, untreated CML, were labelled with murine anti-human LFA-3, or anti-human LFA-I or anti-HLA-DR, and separated by panning into antibody positive and negative cell fractions (15) (16) (Fig. 1,  final column ). Individual CML patients were then studied both before and after treatment with IFNa, to determine if progenitor cell surface LFA-3 expression could be amplified over time following treatment. Progenitor cell surface LFA-3 expression was increased in each ofthree cases studied, to variable extents, after 3-6 mo of therapy (Fig. 2) . These data suggested that treatment with IFNa might partially or completely reverse LFA-3 deficiency on the CML progenitor cells.
Interferon a reverses CML progenitor cell LFA-3 deficiency in vitro. These marrow samples from IFNa-treated CML patients, however, might have contained increased and variable percentages of normal, nonleukemic progenitor cells. Therefore, the observed restoration of progenitor cell LFA-3 expression might have been simply due to sampling oflarge numbers ofnonleukemic progenitors that had been selected in vivo over months of IFNa therapy. We therefore asked whether IFNa creased LFA-3 expression was caused not simply by rapid selective in vitro toxicity to CML progenitors, but by induction of surface LFA-3 expression on previously LFA-3-progenitor cells. This LFA-3 inductive effect was seen at IFNa concentrations from 50-1,000 U/ml, which encompasses peak and trough levels obtained during in vivo patient treatment with IFNa (Fig. 4) . Similar results were obtained in six additional untreated CML patients, with progenitor cell LFA-3 expression increased from 0-13% to 31-96% (Table III) .
Despite these kinetic and quantitative data, we wished to definitively exclude the possibility that IFNa treatment in vitro was selecting for the growth of normal over leukemic progenitor cells in the LFA-3' fraction. In these studies, hematopoietic colonies were grown in methylcellulose, individual colonies were plucked and suspended in PBS, and RNA extracted and split into two aliquots. Reverse transcriptase polymerase chain reaction was used to amplify specific message for abl and bcrabl from the two aliquots. In this assay, RNA from colonies containing cells bearing the Ph chromosomal translocation would contain both abl and bcr-abl mRNAs, while colonies from normal hematopoietic progenitors would contain only abl but not bcr-abl mRNAs. The results revealed that RNA analysis of individual colonies plucked from the LFA-3' fraction following in vitro interferon treatment confirmed that each colony expressed the characteristic bcr-abl transcript as well as the normal abl transcript (Fig. 5) . Thus the LFA-3' progenitor cells arising after IFN, treatment in vitro are indeed leukemic, and therefore reversion of deficient LFA-3 expres- (Fig. 6 ). These data demonstrate that CML progenitor cells fail to stimulate autoreactive T cells, which was predicted from their underexpression of cell surface LFA-3.
Discussion
These data indicate that CML progenitor cells are deficient in their expression of the cell surface cytoadhesion molecule LFA-3 (CD58). This deficiency appears to be ameliorated in patients treated with interferon a. Moreover, treatment of CML bone marrow with IFNa in vitro reverses the LFA-3 defect over the course of24 h, indicating that the effects observed on patients treated with IFNa are not simply the result ofclonal selection in vivo.
LFA-3 is an extremely widely expressed cell surface protein, whose only known function is as the binding ligand for the T cell surface protein CD2 (22, 23 in vivo (14) . Since LFA-3 is so widely expressed, clonal LFA-3 deficiency could lead to escape from T cell-mediated detection and regulation ofnonimmune cellular proliferation in a variety of tissues.
These observations suggest a direct role for interferon",-reversible LFA-3 deficiency in the pathogenesis of stable phase CML. Cellular requirements for alloengraftment suggest that normal human bone marrow contains in the range of 106 stem cells, and hematopoiesis is maintained by the relatively balanced expression of multiple hematopoietic stem cell clones. If the cycling progenitor daughter cells of active stem cells are recognized and modulated by autoreactive T cells, then LFA-3 deficiency might allow CML progenitor cells to escape autorecognition and autoregulation. This would exacerbate even a slight intrinsic proliferative advantage by the CML clone. In this regard, the failure of highly enriched progenitor cells from patients with CML to stimulate autologous T cells proliferation is quite interesting, inasmuch as these autoreactive T cells locally suppress the differentiation of hematopoietic progenitor cells (2 1).
In this context it is noteworthy that paroxysmal nocturnal hemoglobinuria (PNH) cells are deficient in cell surface LFA-3 (24) . While PNH and CML have disparate clinical manifestations, both share the feature that an abnormal clone gradually becomes overrepresented within the bone marrow. This shared deficiency suggests that LFA-3 deficiency might lead to overexpression of individual hematopoietic cell clones, not to elevated circulating blood cell counts per se. Whether the peripheral manifestation ofthe disease includes high white blood cell and platelet counts as in CML, or low blood cell counts and unusual hemolytic sensitivity as in PNH would depend on other pathophysiologic causes distinct from clonal expansion.
Deficient LFA-3 expression might be only one of several cytoadhesion deficiencies contributing to pathophysiologic clonal expansion in CML. Leukocyte alkaline phosphatase and LFA-3, both deficient in CML cells at different stages ofdifferentiation, are two members of a class of membrane proteins which may be anchored to the cell surface by linkage to membrane lipids through phosphatidyl inositol (25, 26) . Other such proteins include the adhesion proteins NCAM and decay accelerating factor (26) . The data ofGordon et al. suggest that primitive hematopoietic cells may adhere to marrow stroma via phospholipase C-sensitive adhesion molecules (11, 12) . While LFA-3 is expressed on most cells through both PI-linked and PI-independent forms (26, 27) , it is possible that quantitatively decreased expression may both account for the results ofour in vitro assays and prevent normal T cell binding in vivo. The present data support the concept that CML cells may suboptimally express critical PI-linked stem cell proteins which mediate adhesion to stromal cells. Deficient expression of such proteins might contribute to the poor survival of CML marrow cultures in vitro and to failure to regulate CML clonal growth in hematopoietic niches in vivo. The present data both lend circumstantial support to such a hypothesis and suggest that IFNa-responsive CML cells might provide a suitable experimental system to isolate such critical adhesion molecules.
In summary, these data indicate that bone marrow progenitor cells from patients with CML fail to normally express cell surface LFA-3, and that this deficiency is ameliorated in vivo and in vitro by IFNa. We hypothesize that this defect may contribute to the clonal advantage enjoyed by the CML stem cell progeny in vivo. Similar deficiencies in yet to be isolated stromal cell cytoadhesion proteins by CML progenitors may lead to the direct isolation of these molecules.
